# Performance Evaluation of a Urine-based Methylation Assay for Urothelial Carcinoma

> **NCT06912672** · — · NOT_YET_RECRUITING · sponsor: **Shanghai Epiprobe Biotechnology Co., Ltd.** · enrollment: 1500 (estimated)

## Conditions studied

- Urothelial Carcinoma

## Interventions

- **DIAGNOSTIC_TEST:** Evaluate the diagnostic performance of EPIPROBE TAGMe DNA Methylation Detection Kit for Urothelial Cancer

## Key facts

- **NCT ID:** NCT06912672
- **Lead sponsor:** Shanghai Epiprobe Biotechnology Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-05-01
- **Primary completion:** 2026-05-01
- **Final completion:** 2026-12-31
- **Target enrollment:** 1500 (ESTIMATED)
- **Last updated:** 2025-04-08

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06912672

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06912672, "Performance Evaluation of a Urine-based Methylation Assay for Urothelial Carcinoma". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT06912672. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*